AVEO ONCOLOGY
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.
AVEO ONCOLOGY
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2001-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.aveooncology.com
Total Employee:
101+
Status:
Active
Contact:
857-400-0101
Total Funding:
560.85 M USD
Technology used in webpage:
Domain Not Resolving HSTS Apple Mobile Web App Capable Apple Mobile Web App Status Bar Style COVID-19 Smart App Banner Apple Mobile Web Clips Startup Comcast WPTouch Pro
Similar Organizations
Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company discovers and develops therapeutics in the field of cancer metabolism.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
ANI Pharmaceuticals
ANI Pharmaceuticals manufactures oral solid dose products, as well as liquids and topicals.
BioVectra
BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients.
CASI Pharmaceuticals
CASI focus on building a pipeline through mutually beneficial business development transactions.
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Rhythm Pharmaceuticals
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Current Advisors List
Board_member
2002-03-01
Advisor
2001-01-01
Board_member
2011-04-01
Board_member
2012-12-01
Board_member
2007-12-01
Current Employees Featured
Kenneth E. Weg Co - Founder & Board of Directors @ AVEO Oncology
Co - Founder & Board of Directors
2001-10-19
Jeb Ledell Chief Operating Officer @ AVEO Oncology
Chief Operating Officer
2021-12-01
Lisa Bruneau Vice President, Financial Accounting and Reporting @ AVEO Oncology
Vice President, Financial Accounting and Reporting
Michael P. Bailey President & Chief Executive Officer @ AVEO Oncology
President & Chief Executive Officer
2015-01-01
Edgar Braendle Chief Medical Officer and Formation of Scientific Advisory Committee @ AVEO Oncology
Chief Medical Officer and Formation of Scientific Advisory Committee
2024-01-01
David Crist Vice President of Sales @ AVEO Oncology
Vice President of Sales
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - AVEO Oncology
New Leaf Venture Partners
New Leaf Venture Partners investment in Post-IPO Equity - AVEO Oncology
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - AVEO Oncology
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - AVEO Oncology
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - AVEO Oncology
Hercules Capital
Hercules Capital investment in Post-IPO Equity - AVEO Oncology
OSI Pharmaceuticals
OSI Pharmaceuticals investment in Venture Round - AVEO Oncology
Venrock
Venrock investment in Series D - AVEO Oncology
Prospect Venture Partners
Prospect Venture Partners investment in Series C - AVEO Oncology
MPM Bio IV NVS Strategic Fund
MPM Bio IV NVS Strategic Fund investment in Series C - AVEO Oncology
Key Employee Changes
Official Site Inspections
http://www.aveooncology.com Semrush global rank: 4.84 M Semrush visits lastest month: 1.8 K
- Host name: ec2-3-139-141-81.us-east-2.compute.amazonaws.com
- IP address: 3.139.141.81
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "AVEO Oncology"
Management Team - Aveo Oncology
Dr. Claudia Lebedinsky serves as Senior Vice President, Head of Clinical Development of AVEO Oncology, an LG Chem company, bringing more than 20 years of experience in oncology and …See details»
Home - Aveo Oncology
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.See details»
About - Aveo Oncology
AVEO Oncology - Crunchbase Company Profile & Funding
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.See details»
AVEO Oncology - LinkedIn
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA ...See details»
AVEO Oncology, an LG Chem company - 2025 ASCO® Annual …
AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 19, 2023, AVEO …See details»
AVEO Oncology
Feb 25, 2025 AVEO Oncology was founded in 2001 in Cambridge, Massachusetts. The company initially focused on discovering and developing novel drugs based on a genetic …See details»
AVEO Oncology Overview | SignalHire Company Profile
AVEO Oncology is a public company that has been in the industry for 23 years. The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. The position …See details»
AVEO Oncology 2025 Company Profile: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for AVEO Oncology. Use the PitchBook Platform to explore the full profile.See details»
Culture - Aveo Oncology
We urge job applicants to carefully check and confirm the credentials of any person or organization that represents itself as being associated with AVEO Oncology before responding …See details»
AVEO Oncology: Passionately Working to Provide a …
Oct 7, 2021 AVEO Oncology is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. IndustryWired has featured Michael Bailey, CEO of AVEO Oncology …See details»
AVEO Oncology Information - RocketReach
AVEO Oncology is a Biotechnology Research, Pharmaceuticals, and Biotechnology company located in Boston, Massachusetts with $61.3 million in revenue and 199 employees. Find top …See details»
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
Oct 18, 2022 The combination of LG Chem’s Life Sciences division and AVEO is expected to create a global oncology organization with a robust portfolio of innovative products supported …See details»
AVEO is a biopharmaceutical company that offers drug …
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables …See details»
Our Science - Aveo Oncology
Our pipeline Our goal is to grow into a global oncology leader with a strong foundational portfolio that provides solutions to unmet needs in the cancer community. AVEO aims to leverage its …See details»
AVEO Oncology, an LG Chem company - ASCO Annual 2024
Jun 3, 2024 AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 19, …See details»
AVEO Oncology Announces Appointment of Chief Medical
Mar 25, 2024 – Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of...See details»
LG Chem’s New US Acquisition AVEO Oncology Sets ... - Business …
Mar 8, 2023 AVEO Oncology, an LG Chem company, has laid out a blueprint to become a global top 20 oncology-focused biopharmaceutical company within five years.See details»
AVEO Oncology Reports Second Quarter 2021 Financial Results …
Aug 5, 2021 The strength of our early commercial launch reflects the execution of our commercial organization and highlights the high unmet need that exists in the indicated …See details»
LG Chem’s New US Acquisition AVEO Oncology Sets Sights On
Mar 8, 2023 AVEO Oncology, an LG Chem company, has laid out a blueprint to become a global top 20 oncology-focused biopharmaceutical company within five years.See details»